Sodium Valproate, Platelet Dysfunction, and Bleeding
- 1 April 1981
- Vol. 22 (2) , 141-146
- https://doi.org/10.1111/j.1528-1157.1981.tb04094.x
Abstract
The antiepileptic drug sodium valproate (VPA) can provoke a thrombocytopenia or platelet dysfunction, with or without hemorrhages. These unwanted side effects are probably infrequent or, at least, have little clinical importance except in patients undergoing surgery. Thromboelastography appears to be a reliable screening test. As hematological abnormalities are often dose related, VPA dosages greater than 40 mg/kg/day are not advised.Keywords
This publication has 12 references indexed in Scilit:
- Interaction between sodium valproate and platelets: a further study.BMJ, 1979
- Thrombocytopenia associated with sodium valproate treatmentAnnals of Neurology, 1979
- IgM platelet autoantibody due to sodium valproate.BMJ, 1978
- Transient Thrombocytopenia in a Child on Sodium ValproateDevelopmental Medicine and Child Neurology, 1978
- FIBRINOGEN DEPLETION WITH SODIUM VALPROATEThe Lancet, 1978
- SODIUM VALPROATE AND PLATELET-COUNTThe Lancet, 1978
- Sodium ValproateDrugs, 1977
- Sodium valproate and platelet function.BMJ, 1976
- Sodium Di‐N‐Propylacetate (DPA) in the Treatment of Epilepsy:A ReviewEpilepsia, 1975
- Idiosyncratic Reactions to the Antiepileptic DrugsEpilepsia, 1975